example.com: Latest News

Bruker’s Novel maXis ETD Sets Dramatic New Records for Intact Protein Characterization and Top-down Sequencing at ASMS

Wed, 26 May 2010 10:47:00 +0200

SALT LAKE CITY, Utah – May 23^rd, 2010 – At the 58th ASMS Conference, Bruker and several collaborating scientists will present a number of milestone achievements in the analysis of intact proteins, including the direct sequencing and characterization using Bruker’s new maXis ETD system. The high mass accuracy, resolving power and dynamic range which are essential to dissect complex patterns of product ions in protein fragmentation allowed, for the first time, performing ETD-based tandem mass spectrometry on biomolecular ions above 60 kDa routinely. These results represent a new record for the mass spectrometric sequencing of intact proteins and unequivocally demonstrate the dramatic advantages of maXis ETD technology in ETD-based top-down protein structural analysis.

“An increasing proportion of new therapies in pharmaceutical development are proteins. At the same time, many first-generation biotherapeutics will soon come off patent protection, and thus the need for rapid and reliable total protein characterization has never been higher,” commented Dr. Michael Schubert, Executive Vice President at Bruker Daltonics. “We believe that the new maXis ETD has unique and unprecedented capabilities that far exceed what’s feasible with intact protein ETD on ion trap/orbitrap hybrid instruments.”

Since the launch of the novel ultra-high resolution (UHR) QqTOF instrument maXis™ at ASMS 2008, a number of leading scientists have taken the opportunity to explore the potential of the unique combination of high mass range, resolution and speed in the direct LCMS examination of recombinant proteins. “The results are extraordinary, and maXis stands alone in this type of analysis,” commented Bruker’s Head of LCMS Applications Development Dr. Carsten Baessmann. “Isotopic definition of proteins over 30kDa and at part-per million mass accuracy under LC conditions are straight-forward now on our maXis ETD, making the confirmation of correct expression unequivocal.”

Several examples will be demonstrated at Bruker’s Users Meeting on Sunday and during the ASMS scientific program. The recent transfer of Bruker’s leading ETD technology to maXis has allowed precise intact protein analysis as well as comprehensive direct protein gas-phase sequencing. An example of particular note is the direct ETD sequence analysis of intact proteins like serotransferrin and monoclonal antibodies up to a MW of 150 kDa featured by Professor Yury Tsybin of the EPFL (Swiss Federal Institute of Technology Lausanne) in his Thursday 8:30 AM oral presentation at ASMS. Further examples of top-down intact protein identification and characterization will be presented in various poster sessions at ASMS.

The maXis ETD will be highlighted at Bruker's Users Meeting on Sunday, May 23^rd, 2010 before the 58^th ASMS Conference on Mass Spectrometry in Salt Lake City, Utah (USA). For more information on Bruker’s User Meeting and other ASMS activities, please visit www.bdal.com/asms2010.

For More Information:

For more information on maXis ETD, please visit www.bdal.com/maXis
For information about Bruker Daltonics and Bruker Corporation (NASDAQ: BRKR), please visit www.bruker.com

Media Contact: Darwin Asa, Ph.D.
Life-Science Marketing Manager, Bruker Daltonics
Tel: +1 (978) 663-3660, ext. 1149
dja@bdal.com

Bruker Features New High Performance Mass Spectrometry Systems and Applications for the Detailed Analysis of Biotherapeutics at ASMS

Wed, 26 May 2010 10:34:00 +0200

SALT LAKE CITY, Utah – May 23^rd, 2010 – At the 58^th ASMS Conference, Bruker unveils a series of new products and application solutions targeted to improve the capabilities of researchers to develop biotherapeutics. As many biotherapeutics currently under development are protein or peptide based, Bruker has applied its extensive expertise in protein analysis to develop solutions for many common tasks in analyzing a protein or peptide based biotherapeutic including:

Analysis of Truncations and Splice Variants
Identification of Point Mutations
Identification of Fusion Proteins
Protein Glycoform Analysis
Glycan Structure Identification
PEGylation Analysis

At ASMS, Bruker will feature systems and applications built on the class leading Flex™ series of MALDI mass spectrometers for direct N- and C-terminal protein sequence analysis utilizing Bruker’s innovative top-down Edmass™ protein sequencing technology. This technique is often able to read dozens of amino acids from the important terminal residues of a protein, regardless of any protein modifications, and is superior in many aspects to traditional Edman sequencing. This application area is further enhanced by the launch of the new faster, highly efficient autoflex speed™ at ASMS designed to increase the productivity and capabilities of development operations.

In addition to the proven micrO-TOF™ and micrO-TOF-QII™ benchtop LCMS ESI-TOF systems, Bruker has applied its maXis™ UHR-TOF and amaZon ETD™ ion trap systems for the analysis of intact proteins and post translational modifications (PTMs). Several key technical presentations will highlight the powerful and unique capabilities of these systems to provide important information for the analysis of potential biotherapeutics. Utilization of the superior resolution (at least 40,000) and mass accuracy (<1 ppm) of the maXis allows for quick, detailed direct analysis of intact proteins of masses up to, and including, monoclonal antibodies. As a further enhancement to its capabilities, the maXis is the only high resolution, high performance MS system fully capable of integration with UHPLC without any comprise in performance. The amaZon ETD can use gentle Electron Transfer Dissociation (ETD) fragmentation methods to quickly and accurately identify and analyze PTMs from biotherapeutics. The amaZon ETD possesses superior sensitivity and speed and can give detailed information about the site of protein modification, and utilize MSⁿ to generate detailed structural information about complex glycans. At ASMS, Bruker will also introduce a revolutionary large protein ETD capability for the maXis platform.

Dr. Clive Seymour, Executive Vice President at Bruker Daltonics, commented: “The combination of new products and extensive application of our mass spectrometry technologies to the analysis of biotherapeutics couldn’t have come at a better time. With the current emphasis in many pharmaceutical and biotech companies on the development of biotherapeutics, the need for better, more efficient tools to analyze these complicated molecules has become acute. We’ve utilized our extensive expertise in protein analytics to create some of the best, most innovative solutions for driving the development of a biotherapeutic in both discovery and development laboratories.”

Many of the products for analyzing biotherapeutics will be highlighted by researchers from various pharmaceutical companies at Bruker's Users Meeting on Sunday, May 23^rd, 2010 before the 58^th ASMS Conference on Mass Spectrometry in Salt Lake City, Utah (USA). For more information on Bruker’s User Meeting and other ASMS activities, please visit www.bdal.com/asms2010.

For More Information:

For more information on solutions for analyzing biotherapeutics, please visit www.bdal.com
For information about Bruker Daltonics and Bruker Corporation (NASDAQ: BRKR), please visit www.bruker.com

Media Contact: Darwin Asa, Ph.D.
Life-Science Marketing Manager, Bruker Daltonics
Tel: +1 (978) 663-3660, ext. 1149
dja@bdal.com

New autoflex speed System Offers High-Throughput Option for MALDI Biotyper Microbial Identification

Wed, 26 May 2010 10:19:00 +0200

SAN DIEGO, California – May 24^th, 2010 – At the 110th General Meeting of the American Society for Microbiology, Bruker announces the autoflex™ speed MALDI-TOF mass spectrometer as a high-throughput option for microbial identification by molecular fingerprinting using Bruker´s MALDI Biotyper platform.

Most MALDI Biotyper customers will continue to utilize Bruker’s economical and easy-to-use benchtop microflex™ MALDI-TOF mass spectrometer. However, for selected high-throughput microbiology laboratories the autoflex speed may be an attractive option due to its even higher throughput, reduced maintenance requirements and further extended uptime. Especially if interfacing to sample preparation robotics for highest laboratory throughput, or even 24/7 walk-away automation is planned for the future, then the autoflex speed is recommended.

Further technical advancements of the autoflex speed for the MALDI Biotyper workflow are:

1 kilohertz proprietary Bruker smartbeam™ solid-state laser and system electronics for a unmatched speed and throughput for high-volume microbiology laboratories,
Proprietary Bruker smartbeam™ laser lifetime specified with >109 laser shots,
MALDI Perpetual™ Ion Source with IR-laser based self-cleaning in only 15 minutes and without additional down-time, as source cleaning can be performed under vacuum,
Automated source cleaning for extended maintenance intervals and enhanced instrument uptime,
Transponder-aided MALDI target tracking;

Dr. Wolfgang Pusch, Vice President for Clinical Research & IVD at Bruker Daltonics, stated: “The autoflex speed represents an important new high-throughput option for MALDI Biotyper bacterial identification in large microbiology laboratories. The smartbeam laser with greater than 109 laser shots is virtually a ‘life time laser’ for the instrument, considering the microbial identification throughput even in large laboratories.”

Mr. Jetze Botma, Chief Executive Officer and Owner of KIESTRA Lab Automation, further commented: “Most of KIESTRA´s current customers request an integration of a MALDI-TOF mass spectrometer in our Total Lab Automation or Workcell Automation projects. With more than 20 years of experience in MALDI-TOF technology Bruker has the competence to fulfil even the highest demands in that respect. In addition to Bruker´s microflex we will in the future also use the autoflex speed, when cutting edge technology is requested in high throughput microbiology laboratories.”

About the Bruker MALDI Biotyper

Bruker’s dedicated MALDI Biotyper solution enables identification, taxonomical classification or dereplication of microorganisms like bacteria, yeasts and fungi. Classification and identification of microorganisms is achieved reliably and fast using high-throughput MALDI-TOF mass spectrometry. Applications include clinical routine microbial identification (in EU only – for research use only elsewhere), environmental and pharmaceutical analysis, taxonomical research, food and consumer product processing and quality control, as well as in marine microbiology. Bruker’s robust MALDI Biotyper method requires minimal sample preparation efforts and offers low cost per sample.

For More Information:

For more information on MALDI Biotyper, please visit www.bdal.com/maldibiotyper
For information about Bruker Daltonics and Bruker Corporation (NASDAQ: BRKR),
please visit www.bruker.com

Media Contact: Karin Hoffmann
MALDI Biotyper Marketing, Bruker Daltonics
Tel: +49-421-2205-2041
kho@bdal.de

Bruker Launches solariX™ FTMS Based MALDI System at ASMS Conference

Wed, 26 May 2010 10:05:00 +0200

SALT LAKE CITY, Utah – May 23^rd, 2010 – At the 58th ASMS Conference, Bruker today announces a novel MALDI molecular imaging system based on the extreme performance of the solariX FTMS. The new MALDI-solariX combines the extreme analytical performance of the solariX FTMS (resolving power > 1,000,000 at m/z 400 at 7.0 tesla field strength) with a robust and highly sensitive MALDI source to provide an unrivalled platform for high performance molecular imaging of small molecules (e.g. drug, metabolites, lipids) in tissue.

The new solariX MALDI source is based on a dual ion funnel design that includes the combination of MALDI and ESI. This unique source is capable of immediate and effortless switching between the two ionization methods. The combination of MALDI with the solariX FTMS addresses a need in the pharmaceutical industry and in academic research institutions for a high performance imaging solution targeted specifically to the tissue distribution of small molecule drugs and metabolites, endogenous metabolic spatial profiling, and lipid imaging.

The solariX MALDI system incorporates the innovative, proprietary smartbeam^TM II laser which includes a robust solid state 1 kHz laser with advanced optics for molecular imaging, for:

Ultra-high mass resolution high-sensitivity small molecule MALDI-MS imaging, without a loss in sensitivity due to MS/MS for selectivity
Sensitivity necessary to detect drugs and metabolites at therapeutic dosages
Fast data acquisition of up to 1 pixel/sec with 1 kHz laser speed
Laser spot sizes down to 20 um allowing high spatial resolution
Instantaneous source switching allowing trouble free changeover from ESI to MALDI
Highly effective workflow including MALDI imaging sample preparation with the Bruker ImagePrep™ station and data acquisition / image processing with FlexImaging™ software
First commercially available software solution for small molecule statistical class imaging utilizing ClinProTools™

By combining molecular imaging with FTMS detection, researchers can utilize ultra-high mass resolving power to separate and analyze molecules of closely related masses in a truly multiplexed approach – observing all molecular species simultaneously. This provides selectivity without compromising sensitivity. Additionally, industry-leading high mass accuracy (< 1 ppm) provides the requisite specificity for elucidating molecular species without the need for time consuming MS/MS. Complete, simultaneous, label-free mapping of drugs and metabolites in tissue can now be conveyed from single MALDI imaging runs at therapeutic dosing levels. For complete confidence in molecular assignment of detected masses, Bruker’s SmartFormula™ software can be used as part of the small molecule imaging workflow for assigning unambiguous elemental formula to detected peaks.

David Wagner, Section Manager of the DMPK group for GlaxoSmithKline, remarked: "We are very excited to be adding this state-of-the-art capability to the analytical analysis portfolio of our group. This instrument will serve as the primary high-performance molecular imaging solution for GSK's development efforts, and will provide unprecedented power for the spatial analysis of target metabolites."

Full automation allows researchers to acquire data in a completely unattended fashion and the unprecedented ease-of-use offered by the solariX FTMS means MALDI data acquisition and imaging workflows require minimal operator effort.

The solariX™ FTMS Based MALDI System will be highlighted at Bruker's Users Meeting on Sunday, May 23^rd, 2010 before the 58th ASMS Conference on Mass Spectrometry in Salt Lake City, Utah (USA). For more information on Bruker’s User Meeting and other ASMS activities, please visit www.bdal.com/asms2010.

For More Information:

For more information on solariX™ FTMS Based MALDI System,
please visit www.bdal.com/solariX
For information about Bruker Daltonics and Bruker Corporation (NASDAQ: BRKR),
please visit www.bruker.com

Media Contact: Darwin Asa, Ph.D.
Life-Science Marketing Manager, Bruker Daltonics
Tel: +1 (978) 663-3660, ext. 1149
dja@bdal.com

Bruker Introduces MS Workstation 7 Software for New Chemical Analysis Gas Chromatography Triple-Quadrupole Mass Spectrometers

Sun, 23 May 2010 10:27:00 +0200

SALT LAKE CITY, Utah – May 23rd, 2010 – At the 58th ASMS Conference, Bruker Daltonics’ new Chemical Analysis business announced the release of MS Workstation 7, the next generation software package for the newly acquired 3x0 series GC triple-quadrupole (GC-QQQ) mass spectrometers. MS Workstation 7 features Scheduled Multiple-Reaction Monitoring (s-MRM), which facilitates method development, maintenance and data reduction tasks for challenging multi-component methods.

Multi-residue analyses are often challenging due to the low levels and diversity of targeted analytes in complex sample matrices. Regardless of the application area, laboratories are typically faced with the challenge of bolstering the number of compounds identified and measured over shorter and shorter analysis times.

Traditionally, triple-quadrupole mass spectrometers have been used for these targeted, multiplexed analyses due to the excellent selectivity, large dynamic range, high sensitivity and low limits of quantitation obtained with multiple reaction monitoring (MRM) in triple-quadrupole MS instruments. However, the number of compounds that can be effectively monitored per chromatographic run by a triple quadrupole MS can be limited by the cycle time of the instrument, the complexity of the sample matrix and the chromatographic peak widths of the analytes, particularly in fast GC separations.

To answer the challenge posed by complex, multi-residue analytical methods, Bruker has developed the s-MRM approach that is available now in MS Workstation 7. This advanced s-MRM capability decreases the number of concurrent MRM transitions, allowing MRMs to be monitored only around their expected retention times. MS Workstation 7 allows instrument cycle and dwell times to be optimized to deliver highest sensitivity on accurate and reproducible results. The s-MRM approach facilitates the monitoring of increased numbers of MRM transitions during an analysis, and can meet the rigors of current fast, multi-residue GC methods, while maintaining highest data quality.

Collin D’Silva, President of the newly-formed Bruker Chemical Analysis Division, stated: “Before our recent acquisition of the former Varian Inc. GC, GC-QQQ-MS and ICP-MS products, we made sure that they were high performance, high quality instruments that provide value in the marketplace. Bruker is committed to accelerating research and development, as well as applications development and validation, so that our chemical analysis products become even more valuable resources for our customers.”
MS Workstation 7 will be highlighted at Bruker's Users Meeting on Sunday, May 23^rd, 2010 before the 58th ASMS Conference on Mass Spectrometry in Salt Lake City, Utah (USA). For more information on Bruker’s User Meeting and other ASMS activities, please visit www.bdal.com/asms2010.

For More Information:

For more information on MS Workstation 7, please visit www.bdal.com.
For information about Bruker Daltonics and Bruker Corporation (NASDAQ: BRKR),
please visit www.bruker.com

Media Contact: Patrick Jeanville, Ph.D.
GC-MS Product Marketing Manager
Bruker Daltonics – Chemical Analysis Division
Tel: +1 (925) 974-7292
patrick.jeanville@bruker.com

Bruker Launches autoflex™ speed MALDI-TOF(/TOF) With 1 kHz Smartbeam Laser

Tue, 18 May 2010 12:48:00 +0200

BILLERICA, Massachusetts – May 18th, 2010 – Bruker today announces the launch of the newest member in the successful Flex™ series of MALDI-TOF mass spectrometers, the autoflex speed. The autoflex speed delivers superior performance by incorporating numerous innovative technology advancements which provide further enhanced data quality, acquisition speed, class-leading mass and dynamic range, and general robust and efficient performance.

The autoflex speed utilizes a 1 kHz smartbeam™-II laser, wide mass range resolving power of up to 26,000 using PAN™ technology, a novel FlashDetector™ system, and a 4 Gs/s digitizer to enable class-leading performance for challenging applications.

The new FAST-SRM mode also provides the autoflex speed with single reaction monitoring capabilities to enhance results for drug imaging in tissues on a MALDI platform. Finally, the autoflex speed achieves the full potential of Edmass™ top-down, intact protein sequencing for long sequence readouts including incorporation of Bruker’s patented T³-Sequencing™ technology.

System configurations can be optimized for a number of different analytical operations and environments utilizing both TOF and TOF/TOF modes for a variety of proteomics, imaging, polymer and small molecule applications.

By leveraging Bruker’s long-standing expertise in high-performance MALDI-TOF mass spectrometry the autoflex speed is designed to dramatically enhance the productivity of laboratories involved in protein sequencing, biomarker discovery, polymer analysis, lipid and glycan analysis, molecular imaging, drug and metabolite tissue distribution, as well as high-throughput MALDI Biotyper microbiological molecular identification. The autoflex speed complements Bruker’s ultimate performance MALDI-TOF/TOF system, the ultrafleXtreme™.

The autoflex speed incorporates a number of key features which enhance its capabilities and value including:

Enhanced Speed with a 1 kHz (kiloHertz) proprietary smartbeam-II solid-state laser and electronics for high throughput applications including LC-MALDI, MALDI Imaging, and high-throughput microbiology ID,
Unique FAST-SRM mode provides single reaction monitoring capabilities for imaging of drugs and metabolites in tissue,
Expanded High-Resolution Mass Range for analysis of polymers and Edmass™ top-down, intact protein sequencing for long sequence readouts,
FlashDetector™ technology to increase resolution and prevent signal saturation for complex samples,
MALDI Perpetual™ Self-cleaning Ion Source cleans the instrument source in minutes to improve system up-time and with minimal operator maintenance,
Optimized Software packages for numerous applications e.g. Protein-, Peptide-, Polymer-Analyses, and MALDI Imaging, clinical research methods and the MALDI Biotyper IVD-CE workflow;

Dr. Ian Sanders, Executive Vice President at Bruker Daltonics, commented: “The new autoflex speed delivers outstanding and robust performance in a very accessible and cost effective platform. This platform can significantly increase the capabilities and effectiveness of analytical groups, particularly those working in biotherapeutics, as well as for basic proteomics and biomarker discovery research. The autoflex speed enhances the reach and capabilities of MALDI-TOF and TOF/TOF, and makes innovative technology readily available and accessible - also for non mass spec experts.”

The autoflex speed will be highlighted at Bruker's Users Meeting on Sunday, May 23rd, 2010 before the 58th ASMS Conference on Mass Spectrometry in Salt Lake City, Utah (USA). For more information on Bruker’s User Meeting and other ASMS activities, please visit www.bdal.com/asms2010.

For More Information:

For more information on autoflex speed, please visit www.bdal.com/autoflex
For information about Bruker Daltonics and Bruker Corporation (NASDAQ: BRKR), please visit www.bruker.com

Media Contact: Darwin Asa, Ph.D.
Life-Science Marketing Manager, Bruker Daltonics
Tel: +1 (978) 663-3660, ext. 1149
E: dja@bdal.com

AGES Selects Bruker's MALDI Biotyper System for Mass Spectrometry-based Molecular Microbial Identification

Mon, 17 May 2010 11:23:00 +0200

VIENNA, May 17, 2010 (BUSINESS WIRE) --At the 32rdOEGHMP annual meeting ("Jahrestagung der Österreichischen Gesellschaft für HYGIENE, MIKROBIOLOGIE und PRÄVENTIVMEDIZIN") opening here today, Bruker announces that its MALDI Biotyper workflow for microbial identification in clinical microbiology has been selected by the Austrian Agency for Health and Food Safety (AGES) for MALDI-TOF based analyses of microorganisms.

AGES is responsible for several tasks in regard to public health and food safety for the Austrian government. The organization researches, analyzes and performs inspections according to the policy guidelines of Austrian Food Laws. The agency requires veterinary inspections and dedicates itself to the prevention and control of infectious diseases in the population. Just recently, scientists of the AGES discovered the source of a listeriosis outbreak in Austria and Germany that caused eight deaths due to contaminated cheese products. In order to provide always state of the art microbiological analyses AGES is the first organization in Austria using the IVD-CE marked IVD MALDI Biotyper system that is in accordance with the European Union In Vitro Diagnostic Directive 98/79/EC.
University Professor Dr. med. Franz Allerberger, Head of the Human Medicine Division, AGES commented: "Microbial analyses based on MALDI-TOF mass spectrometry as a molecular identification tool provide premium information in order to describe and differentiate microorganisms very reliably. With advantages in speed, accuracy and cost per sample over phenotypic standard tests, the MALDI Biotyper has the potential to become a new clinical standard for microbial identification. In particular, for fastidious microorganisms like anaerobic and non-fermenting bacteria the superior discrimination power of the MALDI Biotyper has been proven in several publications. In order to substantiate the MALDI Biotyper benefit especially for difficult species in the daily clinical routine AGES will be the leading organization for quality assurance and standardization for the analysis after Legionella infections. In this context we will also perform a respective round robin test comprising labs from all over the world."

Dr. Guido Mix, Bruker Daltonics Director for Microbiology Business Development, concluded: "The MALDI Biotyper is already a very suitable and reliable tool for daily microbiological routine analysis. Globally more than 100 clinical diagnostic labs, as well as further microbiology departments at industrial and academic sites operate this protein fingerprinting-based approach. We are very pleased to collaborate with an organization like the AGES in order to explore the MALDI Biotyper capabilities beyond current standardized operational species identification procedures, and towards strain typing or clone tracking."

About the Bruker MALDI Biotyper

Bruker's dedicated MALDI Biotyper solution enables identification, taxonomical classification or dereplication of microorganisms like bacteria, yeasts and fungi. Classification and identification of microorganisms is achieved reliably and fast using high-throughput MALDI-TOF mass spectrometry. Applications include clinical routine microbial identification (in EU only - for research use only elsewhere), environmental and pharmaceutical analysis, taxonomical research, food and consumer product processing and quality control, as well as in marine microbiology. Bruker's robust MALDI Biotyper method requires minimal sample preparation efforts and offers low cost per sample. For more information, please visit www.maldibiotyper.com.

For more information about Bruker Daltonics and Bruker Corporation (NASDAQ: BRKR), please visit www.bdal.com and www.bruker.com.

Photos/Multimedia Gallery Available: www.businesswire.com

SOURCE: Bruker Corporation
Bruker Daltonics
Karin Hoffmann, MALDI Biotyper Marketing
Tel: +49-421-2205-2041
kho@bdal.de

Bruker and KIESTRA Lab Automation Announce Alliance in Microbial Identification by MALDI Biotyper Molecular Fingerprinting and Microbiology Lab Automation

Fri, 09 Apr 2010 08:50:00 +0200

VIENNA, Apr 09, 2010 (BUSINESS WIRE) --Prior to the 20th Annual Meeting of the European Society of Clinical Microbiology and Infectious Diseases on April 10-13, 2010 in Vienna, Bruker Daltonics and KIESTRA Lab Automation announce an expanded partnership covering co-marketing and cross-selling of their respective technologies for microbiology routine laboratories, as well as a joint research and development program for interfacing their technologies.

In recent years, Bruker and KIESTRA Lab Automation have worked with a number of customers applying both technologies in their laboratories. Together with the Academical Medical Center (Amsterdam), the Jeroen Bosch Hospital (Den Bosch), Leiden University Medical Center (Leiden) and Streeklab Haarlem (Haarlem), both companies applied for the prestigious European Research Initiative EUREKA (www.eureka.be). Typically, EUREKA R&D is lead by industry and is focused on significant new customer requirements. In March 2010, the participating project partners ranked at third position of the EUREKA tender for their joint 24/7 Bacteriology Identification & Sensitivity System (BISS) project. In addition to integration of both technologies, a goal of the BISS project is to enable unattended 24/7 operation for bacterial identification.

Mr. Jetze Botma, Chief Executive Officer at KIESTRA Lab Automation, stated: "It is remarkable to see how relatively new players in the microbiology market have changed the competitive landscape in the last couple of years. The trends of consolidation of laboratories and of centralizing microbiology laboratory services will further increase the demand for professional automation solutions. In addition, an early identification by the MALDI Biotyper in many cases can already initiate a germ-specific therapy, which leads to a significant increase in laboratory and hospital efficacy. The effective combination of both technologies will help to ease the burden on the healthcare system."

Dr. Wolfgang Pusch, Vice President for Clinical Research Solutions & IVD at Bruker Daltonics, added: "This strategic partnership with KIESTRA Lab Automation is an excellent match for Bruker. We are two leading suppliers offering innovative technologies for the microbiology market, in laboratory automation and in molecular microbial ID. Each of our technologies alone has been quite successful already, and in combination they could change the way microbiology is performed in many routine labs. KIESTRA's technology brings the same level of automation into the microbiology lab that was introduced in clinical chemistry 15 years ago. Moreover, the MALDI Biotyper reduces the identification turnaround time for patient samples significantly. Both technologies integrated together will help microbiology laboratories to perform their important tasks faster and better, despite a predicted shortage in experienced laboratory staff."

About the Bruker MALDI Biotyper

Bruker's proprietary MALDI Biotyper solution enables molecular identification, taxonomical classification or dereplication of microorganisms like bacteria, yeasts and fungi. Classification and identification of microorganisms is achieved reliably and quickly using proteomic fingerprinting by high-throughput MALDI-TOF mass spectrometry. Applications include clinical routine microbial identification, environmental and pharmaceutical analysis, taxonomical research, food and consumer product processing and quality control, as well as marine microbiology. Bruker's robust MALDI Biotyper method requires minimal sample preparation efforts and offers low consumables cost per sample. The MALDI Biotyper is available in a research-use-only version, as well as in an IVD-CE version according to EU directive EC/98/79 in certain European countries. For more information, please visit www.maldibiotyper.com.

For more information about Bruker Daltonics and Bruker Corporation (NASDAQ: BRKR), please visit www.bdal.com and www.bruker.com.

About Kiestra's MalditofA for Fully Automatic Colony Picking

Bruker's MALDI-TOF technology is a true revolution within medical bacteriology. KIESTRA launches a full automatic colony picker, called MalditofA. The automatic transfer of a colony to the target plate by the MalditofA guarantees that possible manual mismatches are prevented. In order to enhance susceptibility testing, the MalditofA also automatically creates the suspension fluid at. e.g. 0.5 McFarland. The MalditofA makes sure laboratories can take advantage to reduce id-card usage while labor costs are reduced dramatically.

For more information about KIESTRA Lab Automation, please visit www.kiestra.nl.

CAUTIONARY STATEMENT OF BRUKER

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, and exposure to foreign currency fluctuations. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2009, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements other than as required by law.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6243451&lang=en

SOURCE: Bruker Daltonics

MALDI Biotyper Marketing, Bruker Daltonics
Karin Hoffmann, +49-421-2205-2041
kho@bdal.de
or
KIESTRA Lab Automation
Anneke Dalstra, +31-512-510-710
adalstra@kiestra.nl

Bruker Announces Formation of New Chemical Analysis Division and Appointment of Collin D'Silva as Division President

Thu, 01 Apr 2010 14:30:00 +0200

FREMONT, Calif., Apr 01, 2010 (BUSINESS WIRE) --Bruker Corporation (NASDAQ: BRKR) announced today that it has created a Chemical Analysis Division within its Bruker Daltonics subsidiary. The new Chemical Analysis Division will be managed by Collin D'Silva as division president, and will be headquartered in Fremont, California.

As previously reported, Bruker and Agilent Technologies, Inc. entered into a definitive asset purchase agreement on March 9, 2010, pursuant to which Bruker will acquire certain product lines of Varian, Inc., which Agilent has committed to divest in connection with obtaining regulatory approval for Agilent's previously announced acquisition of Varian. The Varian product lines to be acquired will become part of the Bruker Chemical Analysis Division, and include ICP-MS systems, laboratory gas chromatography (GC) instruments and GC-triple-quadrupole mass spectrometers.

Collin D'Silva, President of the Bruker Chemical Analyis Division, commented: "We are looking forward to the closing of the Bruker-Agilent transaction, and to welcoming the management teams who are now running the present Varian Lab GC, GC-QQQ-MS and ICP-MS businesses to Bruker's Chemical Analysis Division. Most importantly, we look forward to welcoming the customers of these three product lines, and we are committed to providing the highest level of applications and service support, as well as accelerated applications and product development, to this valued customer base."

Frank Laukien, President and CEO of Bruker Corporation, stated: "These three businesses offer an opportunity to leverage our existing strengths in the analytical instruments market. The three new product lines will form the core offerings of our new Chemical Analysis Division, and we are delighted that Collin has agreed to lead this division with the many talented and highly motivated managers and employees who are expected to join this Chemical Analysis Division from Varian in the next few weeks."

Mr. D'Silva served as Chief Executive Officer of Transgenomic, Inc., a public life sciences instruments company, from 1997 until April 2006. Previously, Mr. D'Silva was founder, President and Chief Executive Officer of CETAC Technologies, Inc, a company designing instrumentation for elemental analysis. Prior to CETAC, Mr. D'Silva held various senior management positions with AT&T Network Systems, including the position of business unit manager of a $350 million annual revenue division. Mr. D'Silva holds a B.S. degree and a Masters in Industrial Engineering from Iowa State University, as well as an M.B.A. from Creighton University.

Mr. D'Silva has been a director of Bruker Corporation since 2000. In order to assume his new responsibilities as division president of the Chemical Analysis Division, Mr. D'Silva stepped down from Bruker's Audit Committee on March 9, 2010, and Mr. D'Silva also has resigned from Bruker's Board of Directors as of March 31, 2010. As a result, the Bruker Board and Audit Committee temporarily are not in compliance with all NASDAQ listing requirements. Bruker has informed NASDAQ accordingly, and Bruker intends to regain compliance within the applicable 180-day cure period.

About Bruker Corporation

Bruker Corporation is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis. For more information about Bruker Corporation, please visit www.bruker.com.

CAUTIONARY STATEMENT

SOURCE: Bruker Corporation

Bruker Corporation
Stacey Desrochers, +1 978-663-3660, ext. 1115
Director of Investor Relations
stacey.desrochers@bruker.com

Bruker Announces New Scientific Instruments and Software, plus Innovative, Turn-Key Analyzers for the Pharma, Food, Solar, Metals and Advanced Materials Industries

Mon, 29 Mar 2010 10:25:00 +0200

MUNICH, Germany, Mar 23, 2010 (BUSINESS WIRE) -- At Analytica 2010, Bruker Corporation (NASDAQ: BRKR) today announces launches of numerous novel scientific instruments and software capabilities, as well as high-performance analytical solutions for applied markets and industrial applications. The new systems introduced today are focused on bringing robust, easy-to-use and affordable turn-key solutions to routine analysis, as well as on opening new scientific horizons for advanced research applications.

Bruker is leveraging its high-performance technologies, applications know-how and close customer collaborations to pioneer innovative and unique analytical solutions that are more compact, easier to use, more productive, more sensitive and feature higher specificity and analytical reliability. These new products address an expanding array of applied, food, petro-chem, pharma-biotech, solar, advanced materials and nanotechnology, as well as academic research and teaching markets.

The new Bruker products and solutions launched at Analytica 2010 include:

Bruker AXS, Bruker Nano and Bruker Elemental:

D8 DISCOVER^TM: the next-generation of Bruker's industry-leading X-Ray Diffraction (XRD) system for high-end materials research, including real-time component detection, plug-and-play functionality and fully integrated 2-dimensional diffraction XRD2, using the novel VANTEC-500 large-area detector;
S2 RANGER^TM: significantly enhanced Energy Dispersive X-Rray Fluorescence (EDXRF) spectrometer with Bruker's new maintenance-free XFlash(R) LE silicon drift detector (SDD) for best-in-class light element analysis for the food, minerals & mining and cement industries;
N8 NEOS^TM: the first atomic force microscope (AFM) that is designed and operated like an optical microscope, with outstanding stability and precision for atomic resolution, all in a compact, integrated systems that combines both optical and AFM microscopy in a single, easy inspection system;
Q2 ION^TM: a compact, best-in-class spark Optical Emission Spectrometer (OES) for incoming material inspection and quality assurance in the metals industry. Its primary applications and matrices include copper, aluminum and iron analysis at smaller foundries, inspection companies, in metal recycling and at metal fabricators.

Bruker BioSpin NMR Spectroscopy:

Fourier 300: an innovative, easy-to-use, affordable 300 MHz spectrometer that brings Fourier transform (FT) Nuclear Magnetic Resonance (NMR) spectroscopy within every chemist's reach. With its new robust Fourier NMR Probe technology, easy TopSpin software, miniaturized electronics and proven magnets, the Fourier 300 is a complete proton and carbon 1D and 2D FT-NMR system that delivers powerful performance for routine labs, satellite labs and colleges.
TopSpin^TM 3.0: next-generation NMR software delivers new modules for Non-Uniform Sampling, Automated Structure Confidence Analysis, Automated Concentration Determination and the new Protein Dynamic Center to transform cutting-edge 'research methods' in small molecule and bio-molecule applications into 'routine tools'. These and other TopSpin 3.0 innovations give researchers and industrial NMR spectroscopists new capabilities for obtaining results significantly faster, more conveniently and with greater accuracy;

Bruker Optics Molecular Spectroscopy:

CryoSAS^TM: this Cryogenic Silicon Analysis System is a unique dedicated FT-IR system for quality control of high-purity silicon materials, optimized for 'at-line' operation in the solar industry;
ALPHA^TM Wine Analyzer: a dedicated, compact FT-IR system for the quality control of wine, featuring a novel measurement mode that is significantly less sensitive to particles and gas bubbles in the sample, and provides more reliable and robust results;

Bruker Daltonics Life-Science Mass Spectrometry:

amaZon^TM SL 'SmartLine': a routine analytical, best-in-class LC/MSn ion trap mass spectrometer for pharma and chemical companies, applied laboratories and academic customers, with proprietary dual ion funnel technology for outstanding sensitivity, UHPLC speed for highest productivity, and fast positive/negative ion switching for more complete analytical coverage. The amaZon SL is designed for laboratories involved with small molecule applications including structural confirmation, compound screening and identification, process and general synthesis control, and metabolite identification.

Frank Laukien, Ph.D., Bruker's President and CEO, commented: "Our new products are expected to further enhance our position in the markets we serve, offering exceptional analytical and research capabilities with greater convenience to our customers. With compact, easy-to-use, affordable, yet high performance products we believe we can gain access to broader markets and expand our presence in many routine quality control, applied and industrial market segments."

For More Information:

For complete press releases and images, please visit http://www.bruker.com/press

For information about Bruker Corporation (NASDAQ: BRKR), please visit www.bruker.com

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6224036&lang=en

SOURCE: Bruker Corporation

Bruker Corporation
 Investor Relations:  
Stacey Desrochers, +1-978-663-3660, ext. 1115 
Director of Investor Relations 
stacey.desrochers@bruker.com 
Media:  
Haydar Kustu, +1-978-439-9899, ext. 5134 
Marketing Manager
 haydar.kustu@bruker.com